Abstract 142P
Background
Pancreatic cancer (PC) remains a major health concern due to its dismal prognosis and high mortality rates. Hypoxia-inducible factor 1-alpha (HIF-1α) is implicated in promoting tumor growth, angiogenesis, and metabolic changes under hypoxic conditions. However, an all-inclusive understanding of HIF-1α's precise role and clinical impact on PC is yet to be ascertained. This study aims to study the influence of HIF-1α on PC. Specifically, the goal is to assess differences in overall survival (OS) and OS in the context of metastasis between PC patients with high and low expression of HIF-1α.
Methods
We comprehensively searched PubMed, Embase, and the Cochrane Library databases for relevant research articles published until December 2022. Studies eligible for inclusion compared clinical outcomes in PC patients expressing high and low levels of HIF-1α. Primary outcomes of interest were OS and OS in patients with metastasis, computed using the hazard ratio (HR). The R software (version 4.0.3) with metafor and meta packages was used for all statistical analyses, utilizing random-effects models.
Results
Our meta-analysis encompassed 16 studies, representing a cohort of 1,080 PC patients, including 566 with high HIF-1α expression and 514 with low HIF-1α expression. The pooled HR for OS was 1.86 (95% CI: 1.64-2.12, P<0.01, I2=0%), indicating significantly lower survival rates among patients expressing high HIF-1α. More crucially, the pooled HR for OS in patients with metastasis was 2.09 (95% CI: 1.67-2.64, P<0.01, I2=0%), suggesting an even poorer survival outcome in metastatic PC patients with high HIF-1α expression.
Conclusions
Our findings highlight the considerable prognostic role of HIF-1α in PC, particularly elucidating its fundamental role in disease progression and prognosis, especially in the context of metastasis. These insights could stimulate the development of innovative therapeutic strategies that target HIF-1α, with potential implications for enhancing survival rates in PC patients. Further studies should validate these findings in larger, prospective cohorts and further investigate the specific mechanisms through which HIF-1α exacerbates PC progression, particularly in metastatic cases.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract